Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

Forex Daily Briefing

US Markets

Stocks To Watch

The Week Ahead



Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News


OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

COVID Fighters Rewarded on Markets

The old adage, "he also serves who only sits and waits," is being severely tested these days with the impatience millions are feeling to see some sort of banishment of the deadly COVID-19.

Thomas Edison’s statement “he also serves who hustles while he waits”, is likely more appropriate. And the plaudits are being directed toward those health-care companies, hustling and making headway on this front.

Health-care concerns pulled ahead of breakeven by 0.4% in U.S. markets, while in Canada, the sector was punished 2.3%.

San Diego-based AXIM Biotechnologies, Inc. (OTC:AXIM), announced Thursday the completion of a study highlighting the performance of NeuCovix, AXIM’s rapid test to measure levels of neutralizing anti-COVID-19 antibodies.

AXIM is an international health-care solutions company targeting oncological and COVID-19 research.

The NeuCovix test was compared to a gold standard pseudovirus-based test. NeuCovix accurately classified serum from patients who strongly neutralized SARS-CoV-2 and serum from patients who poorly neutralized the virus.

Tests using live viruses are considered time-consuming, expensive and require trained personnel in a tightly controlled laboratory environment to measure neutralizing antibodies. But NeuCovix is a portable, low cost, rapid point-of-care test that determines levels of neutralizing antibodies in approximately 10 minutes.

AXIM shares proved truly an all-star in early Thursday afternoon trading, flexing its muscles 19.8 cents, or 32.2%, to 81 cents, on volume of 4.5 million shares.

In Canada, there’s concern for protecting truckers going back to work, transporting goods to and fro.

One firm showing that concern is Calgary-based Sparta Group (TSX-Venture:SAY), which has just signed an exclusive 10-year licensing agreement with NME Ltd. to provide millions of truckers with a “much-needed layer of protection” during the on-going COVID-19 crisis and beyond, according to Thursday’s news release.

The licensed compounds, which are registered with the U.S. Food and Drug Administration, Environmental Protection Agency and Health Canada, have the ability to kill 99.99% of dangerous viruses, bacteria and microbes, including SARS and MRSA, on contact.

The news stimulated small-cap buyers in Canada, which propped the price of SAY up one cent, or 40%, to 3.5 cents, on volume of 797,000 shares.